The price target increase for Amicus Therapeutics by Morgan Stanley indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term. The maintained Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector.